Form 8-K · Current report
Boston Scientific 8-K, filed Jul 27, 2026
- Filed
- CIK
- 0000885725
- Accession no.
- 0000885725-26-000049
Summary
Boston Scientific's board approved a 2026 global restructuring program on July 21, 2026, intended to drive cost efficiencies through supply chain optimization and organizational changes. The plan is expected to produce $700 million to $800 million in pre-tax charges, reduce gross annual pre-tax expenses by about $500 million, and result in some headcount reductions.
Key points
- The board approved the 2026 Restructuring Plan on July 21, 2026, with activities expected to begin in 2026 and be substantially completed by the end of 2029.
- Estimated total pre-tax charges are $700 million to $800 million, of which $600 million to $700 million is expected to be future cash outlays.
- The company expects the plan to reduce gross annual pre-tax expenses by approximately $500 million, with a substantial portion of savings reinvested in strategic growth initiatives.
- Key activities include transferring certain production lines among facilities and targeted functional and organizational transformation.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.05Costs Associated with Exit or Disposal Activities
From the filing
Item 2.05 Costs Associated with Exit or Disposal Activities. On July 21, 2026, the Board of Directors of Boston Scientific Corporation (the “Company”) approved a new global restructuring program (the “2026 Restructuring Plan”). The 2026 Restructuring Plan is intended to support the Company’s efforts to drive sustained cost efficiencies and enable continued growth by ensuring that the Company is structured and resourced to support its strategic priorities. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.